We’re excited to begin recruiting for Incyte’s postdoctoral fellowship programs in partnership with Saint Joseph's University. We’re proud to offer these programs to Pharm.D. and Ph.D. graduates to help cultivate professional growth and Solve On. Applications open on October 1. https://bit.ly/3MBXm1m
About us
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.
- Website
-
http://www.incyte.com
External link for Incyte
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Wilmington, Delaware
- Type
- Public Company
- Specialties
- Oncology, Immuno-oncology, Targeted Therapy, Immunology, and Inflammation
Locations
-
Primary
1801 Augustine Cut-Off
Wilmington, Delaware 19803, US
Employees at Incyte
-
Harry Atkins
Senior Director, Alliance Management, Global Strategy and Corporate Development at Incyte
-
Dana Walters
Medical Regulatory Writer
-
Steven Flostrand
Executive Director, Value, Access & Pricing (Europe) at Incyte
-
Onofrio Mastandrea
Regional Vice President, General Manager | Board Member | Forbes Top 100 Managers 2023
Updates
-
Incyte is dedicated to treating and supporting patients with critical unmet needs, like chronic graft-versus-host disease (#GVHD). Advanced chronic GVHD results in the development of fibrotic tissue across multiple organ systems and can be extremely difficult to treat. https://bit.ly/3TiQZUi
Our Continued Commitment to chronic GVHD Patients
-
Today, we are at the Society of Hematologic Oncology Annual Meeting, where we will present recent data in #hematology. Learn more. https://bit.ly/4dV7Rsr
-
How much do you know about leukemia? We're breaking down the facts about this blood cancer and the impact it can have on patients. Join #TeamIncyte on #WorldLeukemiaDay and learn more. #SolveOnForBloodCancer #BloodCancerAwarenessMonth https://bit.ly/4dObKPX
World Leukemia Day 2024
-
This #BloodCancerAwarenessMonth, we are steadfast in our mission to educate and raise awareness about these serious diseases. Join us this September in our dedication to #SolveOnForBloodCancer. https://bit.ly/3X9uCBX
Recognizing Blood Cancer Awareness Month
-
While hidradenitis suppurativa (HS) is believed to be caused by genetic and environmental factors that disrupt the immune system, the exact cause is unknown, highlighting the importance of advancing research for this condition. Hear Incyte’s Joslyn Kirby, Senior Medical Director, discuss HS and its impact on the 150,000 patients in the U.S. living with this condition. #SolveOn https://bit.ly/3AI1HgE
-
Learn more about the data being presented from our oncology portfolio at the ESMO - European Society for Medical Oncology Congress. #ESMO2024 https://bit.ly/4dRZwVX
-
We’ve announced positive topline results from the Phase 3 inMIND trial in patients with relapsed or refractory follicular lymphoma (FL). Learn more. #News https://bit.ly/46NgHWo
-
The FDA has approved our treatment, with Syndax Pharmaceuticals, for certain patients with chronic graft-versus-host disease (#GVHD). This is our second approved treatment for chronic GVHD and we remain committed to helping those living with this potentially life-threatening condition. #News https://bit.ly/3X1s5dY
-
Join us in celebrating #NationalInternDay as we share a glimpse into the daily experiences and contributions of our interns. Here's to a summer filled with learning, growth, and success—thank you to all our interns for infusing our team with your passion and energy! #IncyteProud
Affiliated pages
Similar pages
Browse jobs
Stock
INCY
NASDAQ
20 minutes delay
$61.26
-1.7 (-2.7%)
- Open
- 63.2
- Low
- 61.19
- High
- 63.76
Data from Refinitiv
See more info on